Emergence of quinolone-resistant strains in Streptococcus pneumoniae isolated from paediatric patients since the approval of oral fluoroquinolones in Japan

Abstract Tosufloxacin (TFLX) is a fluoroquinolone antimicrobial agent. TFLX granules for children were initially released in Japan in 2010 to treat otitis media and pneumonia caused by drug-resistant bacteria, e.g. penicillin-resistant Streptococcus pneumoniae and beta-lactamase-negative, ampicillin...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 2017-04, Vol.23 (4), p.218-223
Hauptverfasser:	Takeuchi, Noriko, Ohkusu, Misako, Hoshino, Tadashi, Naito, Sachiko, Takaya, Akiko, Yamamoto, Tomoko, Ishiwada, Naruhiko
Format:	Artikel
Sprache:	eng
Schlagworte:	Anti-Bacterial Agents - therapeutic use beta-Lactamases - genetics Child Child, Preschool Children Drug Resistance, Bacterial - genetics Female Fluoroquinolones Fluoroquinolones - therapeutic use Genes, Bacterial - genetics Hematology, Oncology and Palliative Medicine Humans Japan Male Pneumococcal Infections - drug therapy Pneumococcal Infections - microbiology Quinolone-resistant Quinolones - therapeutic use Streptococcus pneumoniae Streptococcus pneumoniae - drug effects Streptococcus pneumoniae - genetics Streptococcus pneumoniae - isolation & purification
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!